✨ Free AI Report
Innoviva, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Innoviva, Inc.
Company Research

Innoviva, Inc.: Business Overview, Financials & Competitive Analysis

Innoviva is a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (IST), and a portfolio of strategic...

Analyst-debate audio for Innoviva, Inc.

AskCyborg analysts argue the bull and bear cases for Innoviva, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Strong

Cyborg Score thesis

Dual-engine growth model combining stable royalty income with high-growth infectious disease and critical care platform drives...

Read the full analyst-debate transcript →
Industry Biopharmaceutical Manufacturing & Specialty Therapeutics
2 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Innoviva, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Innoviva, Inc. Overview

Pro stress-test →

Innoviva is a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (IST), and a portfolio of strategic investments in healthcare assets. The company demonstrated strength across all areas in 2025 with 15% revenue growth to over $400 million, stable royalty cash flow, and IST generated 47% year-over-year U.S. sales growth to $119 million.

Strategic Profile

Pro stress-test →

Innoviva's royalties portfolio centers on respiratory assets partnered with Glaxo Group Limited (GSK), providing ongoing revenue from RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA® sales. Through its specialty therapeutics division, Innoviva commercializes critical care and infectious disease products including GIAPREZA, XERAVA, XACDURO, and ZEVTERA, with recent FDA approval of NUZOLVENCE for uncomplicated urogenital gonorrhea.

Competitive Landscape

Pro stress-test →

Innoviva competes in respiratory therapy market (RELVAR/BREO, ANORO ELLIPTA), critical care vasoconstriction (GIAPREZA vs other vasopressors), and infectious disease treatment (XERAVA, XACDURO, ZEVTERA, NUZOLVENCE) against established pharmaceutical companies and specialty biotech firms.

Industry Context

Innoviva, Inc. operates in Biopharmaceutical Manufacturing & Specialty Therapeutics.

Key facts

Founded: 1996 · Headquarters: Burlingame, California, United States · Employees: 127 · Revenue: $411.3M · Market cap: $1.8B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Innoviva, Inc..

  • FDA approved NUZOLVENCE® (zoliflodacin), a first-in-class, single-dose oral medication for uncomplicated urogenital gonorrhea in adults and pediatric patients 12 years and older.
  • IST U.S. net product sales grew 47% YoY to $119.2M, demonstrating strong commercialization momentum.
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Participated in Oppenheimer 36th Annual Healthcare Life Sciences Conference
  • December 2025Reported full year 2025 financial results with 15% revenue growth to $411.3M and net income $271.2M
  • +1 moreTrack every material event for Innoviva, Inc. as it happens. Explore monitoring →
Get alerted when Innoviva, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

BREO ELLIPTA / ANORO ELLIPTARespiratory combination therapies in same product class→Other vasopressors and antibioticsCompetitive products in critical care and infectious disease→

Compare Innoviva, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Innoviva, Inc. operates in Biopharmaceutical Manufacturing & Specialty Therapeutics. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical Manufacturing & Specialty Therapeutics research →
NEW · MCP server

Ask your AI assistant about Innoviva, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Innoviva, Inc. and its top competitor on Cyborg Score”
“What did Innoviva, Inc. do this quarter?”
“Is Innoviva, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Innoviva, Inc. do?+
Innoviva is a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (IST), and a portfolio of strategic...
What is Innoviva, Inc.'s Cyborg Score?+
Innoviva, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Innoviva, Inc.'s main competitors?+
Named competitors include BREO ELLIPTA / ANORO ELLIPTA, Other vasopressors and antibiotics. The full competitive landscape is in the AskCyborg report.
How can I get the full Innoviva, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Innoviva, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Innoviva, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.